AB 2589: Controlled substances: human chorionic gonadotropin.
- Session Year: 2017-2018
- House: Assembly
- Latest Version Date: 2018-07-09
Under the existing California Uniform Controlled Substances Act, controlled substances are listed on 5 different schedules. Existing law lists human chorionic gonadotropin (hCG) as a Schedule III controlled substance. Substances listed as controlled substances are subject to various forms of regulation, including reporting requirements, prescribing requirements, and criminal prohibitions on possession.
This bill would exempt hCG from being subject to the reagent regulations of the Controlled Substances Act when possessed by, sold to, purchased by, transferred to, or administered by a licensed veterinarian, or a licensed veterinarians designated agent, exclusively for veterinary use.
Under the existing California Uniform Controlled Substances Act, controlled substances are listed on 5 different schedules. Existing law lists human chorionic gonadotropin (hCG) as a Schedule III controlled substance. Substances listed as controlled substances are subject to various forms of regulation, including reporting requirements, prescribing requirements, and criminal prohibitions on possession.
This bill would exempt hCG from being subject to the reagent regulations of the Controlled Substances Act when possessed by, sold to, purchased by, transferred to, or administered by a licensed veterinarian, or a licensed veterinarians designated agent, exclusively for veterinary use.
Under the existing California Uniform Controlled Substances Act, controlled substances are listed on 5 different schedules. Existing law lists human chorionic gonadotropin (hCG) as a Schedule III controlled substance. Substances listed as controlled substances are subject to various forms of regulation, including reporting requirements, prescribing requirements, and criminal prohibitions on possession.
This bill would exempt hCG from being subject to the reagent regulations of the Controlled Substances Act when it is expressly purchased, sold, possessed, transferred, or administered for specified veterinary purposes. possessed by, sold to, purchased by, transferred to, or administered by a licensed veterinarian, or a licensed veterinarians designated agent, exclusively for veterinary use.
Under the existing California Uniform Controlled Substances Act, controlled substances are listed on 5 different schedules. Existing law lists human chorionic gonadotropin (hCG) as a Schedule III controlled substance. Substances listed as controlled substances are subject to various forms of regulation, including reporting requirements, prescribing requirements, and criminal prohibitions on possession.
This bill would exempt hCG from being subject to the reagent regulations of the Controlled Substances Act when it is expressly purchased, sold, possessed, transferred, or administered for specified veterinary purposes.
Existing law declares that significant public benefit would be derived if private, not-for-profit hospitals periodically reviewed and reaffirmed their commitment to assist in meeting their communities health care needs by identifying and documenting benefits provided to the communities that they serve, and requires each hospital to annually adopt and update a community benefits plan for providing community benefits either alone, in conjunction with other health care providers, or through other organizational arrangements. Each hospital is also required to annually submit its community benefits plan, including a description of the activities that the hospital has undertaken in order to address community needs within its mission and financial capacity, to the Office of Statewide Health Planning and Development.This bill would make technical, nonsubstantive changes to those provisions.Existing law declares that significant public benefit would be derived if private, not-for-profit hospitals periodically reviewed and reaffirmed their commitment to assist in meeting their communities health care needs by identifying and documenting benefits provided to the communities that they serve, and requires each hospital to annually adopt and update a community benefits plan for providing community benefits either alone, in conjunction with other health care providers, or through other organizational arrangements. Each hospital is also required to annually submit its community benefits plan, including a description of the activities that the hospital has undertaken in order to address community needs within its mission and financial capacity, to the Office of Statewide Health Planning and Development.
This bill would make technical, nonsubstantive changes to those provisions.
(a)The controlled substances listed in this section are included in Schedule III.
(b)Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of those isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1)Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or that is the same except that it contains a lesser quantity of controlled substances.
(2)Benzphetamine.
(3)Chlorphentermine.
(4)Clortermine.
(5)Mazindol.
(6)Phendimetrazine.
(c)Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system:
(1)Any compound, mixture, or preparation containing any of the following:
(A)Amobarbital
(B)Secobarbital
(C)Pentobarbital
or any salt thereof and one or more other active medicinal ingredients that are not listed in any schedule.
(2)Any suppository dosage form containing any of the following:
(A)Amobarbital
(B)Secobarbital
(C)Pentobarbital
or any salt of any of these drugs and approved by the federal Food and Drug Administration for marketing only as a suppository.
(3)Any substance that contains any quantity of a derivative of barbituric acid or any salt thereof.
(4)Chlorhexadol.
(5)Lysergic acid.
(6)Lysergic acid amide.
(7)Methyprylon.
(8)Sulfondiethylmethane.
(9)Sulfonethylmethane.
(10)Sulfonmethane.
(11)Gamma hydroxybutyric acid, and its salts, isomers and salts of isomers, contained in a drug product for which an application has been approved under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 355).
(d)Nalorphine.
(e)Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
(1)Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.
(2) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(3)Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.
(4)Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts. Additionally, oral liquid preparations of dihydrocodeinone containing the above specified amounts may not contain as its nonnarcotic ingredients two or more antihistamines in combination with each other.
(5)Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.
(6)Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(7)Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(8)Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(f)Anabolic steroids and chorionic gonadotropin. Any material, compound, mixture, or preparation containing chorionic gonadotropin or an anabolic steroid (excluding anabolic steroid products listed in the Table of Exempt Anabolic Steroid Products (Section 1308.34 of Title 21 of the Code of Federal Regulations), as exempt from the federal Controlled Substances Act (Section 801 and following of Title 21 of the United States Code)), including, but not limited to, the following:
(1)Androisoxazole.
(2)Androstenediol.
(3)Bolandiol.
(4)Bolasterone.
(5) Boldenone.
(6)Chlormethandienone.
(7)Clostebol.
(8)Dihydromesterone.
(9)Ethylestrenol.
(10)Fluoxymesterone.
(11)Formyldienolone.
(12)4-Hydroxy-19-nortestosterone.
(13)Mesterolone.
(14)Methandriol.
(15)Methandrostenolone.
(16)Methenolone.
(17)17-Methyltestosterone.
(18)Methyltrienolone.
(19)Nandrolone.
(20)Norbolethone.
(21)Norethandrolone.
(22)Normethandrolone.
(23)Oxandrolone.
(24)Oxymestrone.
(25)Oxymetholone.
(26)Quinbolone.
(27)Stanolone.
(28)Stanozolol.
(29)Stenbolone.
(30)Testosterone.
(31)Trenbolone.
(32)Human chorionic gonadotropin (hCG), except when possessed by, sold to, purchased by, transferred to, or administered by a licensed veterinarian, or a licensed veterinarians designated agent, exclusively for veterinary use.
(g)Ketamine. Any material, compound, mixture, or preparation containing ketamine.
(h)Hallucinogenic substances. Any of the following hallucinogenic substances: dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the federal Food and Drug Administration.
(a)The controlled substances listed in this section are included in Schedule III.
(b)Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of those isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1)Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or that is the same except that it contains a lesser quantity of controlled substances.
(2)Benzphetamine.
(3)Chlorphentermine.
(4)Clortermine.
(5)Mazindol.
(6)Phendimetrazine.
(c)Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system:
(1)Any compound, mixture, or preparation containing any of the following:
(A)Amobarbital
(B)Secobarbital
(C)Pentobarbital
or any salt thereof and one or more other active medicinal ingredients that are not listed in any schedule.
(2)Any suppository dosage form containing any of the following:
(A)Amobarbital
(B)Secobarbital
(C)Pentobarbital
or any salt of any of these drugs and approved by the federal Food and Drug Administration for marketing only as a suppository.
(3)Any substance that contains any quantity of a derivative of barbituric acid or any salt thereof.
(4)Chlorhexadol.
(5)Lysergic acid.
(6)Lysergic acid amide.
(7)Methyprylon.
(8)Sulfondiethylmethane.
(9)Sulfonethylmethane.
(10)Sulfonmethane.
(11)Gamma hydroxybutyric acid, and its salts, isomers and salts of isomers, contained in a drug product for which an application has been approved under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 355).
(d)Nalorphine.
(e)Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
(1)Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.
(2) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(3)Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.
(4)Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts. Additionally, oral liquid preparations of dihydrocodeinone containing the above specified amounts may not contain as its nonnarcotic ingredients two or more antihistamines in combination with each other.
(5)Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.
(6)Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(7)Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(8)Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(f)Anabolic steroids and chorionic gonadotropin. Any material, compound, mixture, or preparation containing chorionic gonadotropin or an anabolic steroid (excluding anabolic steroid products listed in the Table of Exempt Anabolic Steroid Products (Section 1308.34 of Title 21 of the Code of Federal Regulations), as exempt from the federal Controlled Substances Act (Section 801 and following of Title 21 of the United States Code)), including, but not limited to, the following:
(1)Androisoxazole.
(2)Androstenediol.
(3)Bolandiol.
(4)Bolasterone.
(5) Boldenone.
(6)Chlormethandienone.
(7)Clostebol.
(8)Dihydromesterone.
(9)Ethylestrenol.
(10)Fluoxymesterone.
(11)Formyldienolone.
(12)4-Hydroxy-19-nortestosterone.
(13)Mesterolone.
(14)Methandriol.
(15)Methandrostenolone.
(16)Methenolone.
(17)17-Methyltestosterone.
(18)Methyltrienolone.
(19)Nandrolone.
(20)Norbolethone.
(21)Norethandrolone.
(22)Normethandrolone.
(23)Oxandrolone.
(24)Oxymestrone.
(25)Oxymetholone.
(26)Quinbolone.
(27)Stanolone.
(28)Stanozolol.
(29)Stenbolone.
(30)Testosterone.
(31)Trenbolone.
(32)Human chorionic gonadotropin (hCG), except when possessed by, sold to, purchased by, transferred to, or administered by a licensed veterinarian, or a licensed veterinarians designated agent, exclusively for veterinary use.
(g)Ketamine. Any material, compound, mixture, or preparation containing ketamine.
(h)Hallucinogenic substances. Any of the following hallucinogenic substances: dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the federal Food and Drug Administration.
(a)The controlled substances listed in this section are included in Schedule III.
(b)Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of those isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1)Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or that is the same except that it contains a lesser quantity of controlled substances.
(2)Benzphetamine.
(3)Chlorphentermine.
(4)Clortermine.
(5)Mazindol.
(6)Phendimetrazine.
(c)Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system:
(1)Any compound, mixture, or preparation containing any of the following:
(A)Amobarbital
(B)Secobarbital
(C)Pentobarbital
or any salt thereof and one or more other active medicinal ingredients that are not listed in any schedule.
(2)Any suppository dosage form containing any of the following:
(A)Amobarbital
(B)Secobarbital
(C)Pentobarbital
or any salt of any of these drugs and approved by the federal Food and Drug Administration for marketing only as a suppository.
(3)Any substance that contains any quantity of a derivative of barbituric acid or any salt thereof.
(4)Chlorhexadol.
(5)Lysergic acid.
(6)Lysergic acid amide.
(7)Methyprylon.
(8)Sulfondiethylmethane.
(9)Sulfonethylmethane.
(10)Sulfonmethane.
(11)Gamma hydroxybutyric acid, and its salts, isomers and salts of isomers, contained in a drug product for which an application has been approved under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 355).
(d)Nalorphine.
(e)Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
(1)Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.
(2) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(3)Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.
(4)Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts. Additionally, oral liquid preparations of dihydrocodeinone containing the above specified amounts may not contain as its nonnarcotic ingredients two or more antihistamines in combination with each other.
(5)Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.
(6)Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(7)Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(8)Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(f)Anabolic steroids and chorionic gonadotropin. Any material, compound, mixture, or preparation containing chorionic gonadotropin or an anabolic steroid (excluding anabolic steroid products listed in the Table of Exempt Anabolic Steroid Products (Section 1308.34 of Title 21 of the Code of Federal Regulations), as exempt from the federal Controlled Substances Act (Section 801 and following of Title 21 of the United States Code)), including, but not limited to, the following:
(1)Androisoxazole.
(2)Androstenediol.
(3)Bolandiol.
(4)Bolasterone.
(5) Boldenone.
(6)Chlormethandienone.
(7)Clostebol.
(8)Dihydromesterone.
(9)Ethylestrenol.
(10)Fluoxymesterone.
(11)Formyldienolone.
(12)4-Hydroxy-19-nortestosterone.
(13)Mesterolone.
(14)Methandriol.
(15)Methandrostenolone.
(16)Methenolone.
(17)17-Methyltestosterone.
(18)Methyltrienolone.
(19)Nandrolone.
(20)Norbolethone.
(21)Norethandrolone.
(22)Normethandrolone.
(23)Oxandrolone.
(24)Oxymestrone.
(25)Oxymetholone.
(26)Quinbolone.
(27)Stanolone.
(28)Stanozolol.
(29)Stenbolone.
(30)Testosterone.
(31)Trenbolone.
(32)Human chorionic gonadotropin (hCG). Except when possessed, sold, purchased, transferred, or administered with the express intention and purpose of injection or implantation into cattle or any other nonhuman species, if that use is approved by the federal Food and Drug Administration. (hCG), except when possessed by, sold to, purchased by, transferred to, or administered by a licensed veterinarian, or a licensed veterinarians designated agent, exclusively for veterinary use.
(g)Ketamine. Any material, compound, mixture, or preparation containing ketamine.
(h)Hallucinogenic substances. Any of the following hallucinogenic substances: dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the federal Food and Drug Administration.
(a) The controlled substances listed in this section are included in Schedule III.
(b) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of those isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or which that is the same except that it contains a lesser quantity of controlled substances.
(2) Benzphetamine.
(3) Chlorphentermine.
(4) Clortermine.
(5) Mazindol.
(6) Phendimetrazine.
(c) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which that contains any quantity of the following substances having a depressant effect on the central nervous system:
(1) Any compound, mixture, or preparation containing any of the following:
(A) Amobarbital
(B) Secobarbital
(C) Pentobarbital
or any salt thereof and one or more other active medicinal ingredients which that are not listed in any schedule.
(2) Any suppository dosage form containing any of the following:
(A) Amobarbital
(B) Secobarbital
(C) Pentobarbital
or any salt of any of these drugs and approved by the federal Food and Drug Administration for marketing only as a suppository.
(3) Any substance which that contains any quantity of a derivative of barbituric acid or any salt thereof.
(4) Chlorhexadol.
(5) Lysergic acid.
(6) Lysergic acid amide.
(7) Methyprylon.
(8) Sulfondiethylmethane.
(9) Sulfonethylmethane.
(10) Sulfonmethane.
(11) Gamma hydroxybutyric acid, and its salts, isomers and salts of isomers, contained in a drug product for which an application has been approved under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 355).
(d) Nalorphine.
(e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
(1) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.
(2) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(3) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.
(4) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts. Additionally, oral liquid preparations of dihydrocodeinone containing the above specified amounts may not contain as its nonnarcotic ingredients two or more antihistamines in combination with each other.
(5) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.
(6) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(7) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(8) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(f) Anabolic steroids and chorionic gonadotropin. Any material, compound, mixture, or preparation containing chorionic gonadotropin or an anabolic steroid (excluding anabolic steroid products listed in the Table of Exempt Anabolic Steroid Products (Section 1308.34 of Title 21 of the Code of Federal Regulations), as exempt from the federal Controlled Substances Act (Section 801 and following of Title 21 of the United States Code)), including, but not limited to, the following:
(1) Androisoxazole.
(2) Androstenediol.
(3) Bolandiol.
(4) Bolasterone.
(5) Boldenone.
(6) Chlormethandienone.
(7) Clostebol.
(8) Dihydromesterone.
(9) Ethylestrenol.
(10) Fluoxymesterone.
(11) Formyldienolone.
(12) 4-Hydroxy-19-nortestosterone.
(13) Mesterolone.
(14) Methandriol.
(15) Methandrostenolone.
(16) Methenolone.
(17) 17-Methyltestosterone.
(18) Methyltrienolone.
(19) Nandrolone.
(20) Norbolethone.
(21) Norethandrolone.
(22) Normethandrolone.
(23) Oxandrolone.
(24) Oxymestrone.
(25) Oxymetholone.
(26) Quinbolone.
(27) Stanolone.
(28) Stanozolol.
(29) Stenbolone.
(30) Testosterone.
(31) Trenbolone.
(32) Chorionic Gonadotropin (HGC). Human chorionic gonadotropin (hCG). Except when possessed, sold, purchased, transferred, or administered with the express intention and purpose of injection or implantation into cattle or any other nonhuman species, if that use is approved by the federal Food and Drug Administration.
(g) Ketamine. Any material, compound, mixture, or preparation containing ketamine.
(h) Hallucinogenic substances. Any of the following hallucinogenic substances: dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the federal Food and Drug Administration.
SECTION 1.Section 127340 of the Health and Safety Code is amended to read:127340.The Legislature finds and declares all of the following:(a)Private, not-for-profit hospitals meet certain needs of their communities through the provision of essential health care and other services. Public recognition of their unique status has led to favorable tax treatment by the government. In exchange, nonprofit hospitals assume a social obligation to provide community benefits in the public interest.(b)Hospitals and the environment in which they operate have undergone dramatic changes. The pace of change will accelerate in response to health care reform. In light of this, significant public benefit would be derived if private, not-for-profit hospitals periodically reviewed and reaffirmed their commitment to assist in meeting their communities health care needs by identifying and documenting benefits provided to the communities that they serve.(c)Californias private, not-for-profit hospitals provide a wide range of benefits to their communities in addition to those reflected in the financial data reported to the state.(d)Unreported community benefits that are often provided but not otherwise reported include, but are not limited to, all of the following:(1)Community-oriented wellness and health promotion.(2)Prevention services, including, but not limited to, health screening, immunizations, school examinations, and disease counseling and education.(3)Adult day care.(4)Child care.(5)Medical research.(6)Medical education.(7)Nursing and other professional training.(8)Home-delivered meals to the homebound.(9)Sponsorship of free food, shelter, and clothing to the homeless.(10)Outreach clinics in socioeconomically depressed areas.(e)Direct provision of goods and services, as well as preventive programs, should be emphasized by hospitals in the development of community benefit plans.The Legislature finds and declares all of the following:
(a)Private Private, not-for-profit hospitals meet certain needs of their communities through the provision of essential health care and other services. Public recognition of their unique status has led to favorable tax treatment by the government. In exchange, nonprofit hospitals assume a social obligation to provide community benefits in the public interest.
(b)Hospitals and the environment in which they operate have undergone dramatic changes. The pace of change will accelerate in response to health care reform. In light of this, significant public benefit would be derived if private private, not-for-profit hospitals periodically reviewed and reaffirmed periodically their commitment to assist in meeting their communities health care needs by identifying and documenting benefits provided to the communities which that they serve.
(c)Californias private private, not-for-profit hospitals provide a wide range of benefits to their communities in addition to those reflected in the financial data reported to the state.
(d)Unreported community benefits that are often provided but not otherwise reported include, but are not limited to, all of the following:
(1)Community-oriented wellness and health promotion.
(2)Prevention services, including, but not limited to, health screening, immunizations, school examinations, and disease counseling and education.
(3)Adult day care.
(4)Child care.
(5)Medical research.
(6)Medical education.
(7)Nursing and other professional training.
(8)Home-delivered meals to the homebound.
(9)Sponsorship of free food, shelter, and clothing to the homeless.
(10)Outreach clinics in socioeconomically depressed areas.
(e)Direct provision of goods and services, as well as preventive programs, should be emphasized by hospitals in the development of community benefit plans.
|
Date
|
Status
|
|---|---|
| Jul 9, 2018 | Chaptered by Secretary of State - Chapter 81, Statutes of 2018. |
| Jul 9, 2018 | Approved by the Governor. |
| Jun 29, 2018 | Enrolled and presented to the Governor at 3 p.m. |
| Jun 25, 2018 | In Assembly. Ordered to Engrossing and Enrolling. |
| Jun 25, 2018 | Read third time. Passed. Ordered to the Assembly. |
| Jun 14, 2018 | Read second time. Ordered to Consent Calendar. |
| Jun 13, 2018 | From committee: Do pass. To Consent Calendar. (Ayes 7. Noes 0.) (June 12). |
| May 3, 2018 | Referred to Com. on PUB. S. |
| Apr 23, 2018 | In Senate. Read first time. To Com. on RLS. for assignment. |
| Apr 23, 2018 | Read third time. Passed. Ordered to the Senate. |
| Apr 18, 2018 | Read second time. Ordered to Consent Calendar. |
| Apr 17, 2018 | From committee: Do pass. To Consent Calendar. (Ayes 7. Noes 0.) (April 17). |
| Apr 11, 2018 | Re-referred to Com. on PUB. S. |
| Apr 10, 2018 | From committee chair, with author's amendments: Amend, and re-refer to Com. on PUB. S. Read second time and amended. |
| Apr 2, 2018 | Re-referred to Com. on PUB. S. |
| Mar 22, 2018 | Referred to Com. on PUB. S. |
| Feb 16, 2018 | From printer. May be heard in committee March 18. |
| Feb 15, 2018 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jun 25, 2018 | Consent Calendar AB2589 Bigelow | Senate Floor |
Passed |
|
| Jun 12, 2018 | Do pass and be ordered to the Consent Calendar | Senate Standing Committee on Public Safety |
Passed |
|
| Apr 23, 2018 | AB 2589 BIGELOW Consent Calendar Second Day Regular Session | Assembly Floor |
Passed |
|
| Apr 17, 2018 | Do pass. To Consent Calendar. | Assembly Standing Committee on Public Safety |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| California Veterinary Medical Association | ** Support | Jun 15, 2018 |
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB |
CONSENT
Bill No: AB 2589
:
SENATE PUBLIC SAFETY COMMITTEE: 7-0, 6/12/18
AYES: Skinner, Anderson, Bradford, Jackson, Mitchell, Stone, Wiener
ASSEMBLY FLOOR: 75-0, 4/23/18 (Consent) - See last page for vote
SOURCE: California Veterinary Medical Association
DIGEST:
This bill exempts human chorionic gonadotropin (hCG) from the regulations associated with Schedule III controlled substances when possessed by, sold to, purchased by, transferred to, or administered by a licensed veterinarian, or a licensed veterinarian’s designated agent, exclusively for veterinary use.
Existing law:
- Classifies controlled substances in five schedules according to their danger and potential for abuse. Schedule I controlled substances have the greatest restrictions and penalties, including prohibiting the prescribing of a Schedule I controlled substance. (Health & Saf. Code, §§ 11054-11058.)
- Classifies hCG as a Schedule III controlled substance. (Health & Saf. Code, § 11056, subd. (f)(32).)
- Makes the possession of a Schedule III controlled substance a misdemeanor, unless upon the prescription physician, dentist, podiatrist, or veterinarian, licensed to practice in this state, and punishable by imprisonment in a county jail for a period of not more than one year, except that such person may instead be punished pursuant to Penal Code section 1170 (h) if that person has one or more prior convictions for specified offenses. (Health & Saf. Code § 11377, subd. (a).)
This bill exempts hCG from the regulations associated with Schedule III controlled substances when possessed by, sold to, purchased by, transferred to, or administered by a licensed veterinarian, or a licensed veterinarian’s designated agent, exclusively for veterinary use.
Background
Controlled Substance Schedules. Through the Controlled Substances Act of 1970, the federal government regulates the manufacture, distribution and dispensing of controlled substances. The Act groups drugs into five schedules with decreasing potential for physical or psychological harm, based on three considerations: (a) their potential for abuse; (b) their accepted medical use; and, (c) their accepted safety under medical supervision. Federal law includes relatively detailed explanations of the factors and standards for placement of drugs in the various schedules.
- Schedule I controlled substances, such as heroin, ecstasy, and LSD, have a high potential for abuse and no generally accepted medical use.
- Schedule II controlled substances have a currently accepted medical use in treatment, or a currently accepted medical use with severe restrictions, and have a high potential for abuse and psychological or physical dependence. Schedule II drugs can be narcotics or non-narcotic. Examples of Schedule II controlled substances include morphine, methadone, Ritalin, Demerol, Dilaudid, Percocet, Percodan, and Oxycontin.
- Schedule III and IV controlled substances have a currently accepted medical use in treatment, less potential for abuse but are known to be mixed in specific ways to achieve a narcotic-like effect. Examples include drugs include Vicodin, Xanax, Ambien and other anti-anxiety drugs.
- Schedule V controlled substances have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics.
Scheduling of Controlled Substances. California classifies controlled substances in five schedules according to their danger and potential for abuse. Schedule I controlled substances have the greatest restrictions and penalties, including prohibiting the prescribing of a Schedule I controlled substance. California does not have formal controlled substance classification procedure. Instead, California relies on the federal controlled substance schedule to determine the appropriateness of scheduling a particular substance.
21 United States Codes Section 811 gives the United States Attorney General the authority to add a controlled substance to the schedule or transfer a controlled substance between the schedules according to specific criteria. Before initiating proceedings to control a drug or other substance, remove a drug or other substance from the schedules, and after gathering the necessary data, the Attorney General requests from the Secretary of Health and Human Services a scientific and medical evaluation, and his or her recommendations, as to whether such drug or other substance should be so controlled or removed. The recommendations are required to include a recommendation with respect to the appropriate schedule. If the Attorney General determines if these facts and all other relevant data constitute substantial evidence of potential for abuse such as to warrant control or removal, he or she shall initiate proceedings for control or removal as the case may be.
The Attorney General is required to consider the following with respect to each drug or substance proposed to be controlled or removed from the schedules:
- Its actual or relative potential for abuse;
- Scientific evidence of its pharmacological effect, if known;
- The state of current scientific knowledge regarding the drug or other substance;
- Its history and current pattern of abuse;
- The scope, duration, and significance of abuse;
- What, if any, risk there is to the public health;
- Its psychic or physiological dependence liability; and,
- Whether the substance is an immediate precursor of a substance already controlled under this subchapter.
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
California Veterinary Medical Association (source)
OPPOSITION: (Verified 6/13/18)
None received
ASSEMBLY FLOOR: 75-0, 4/23/18
AYES: Acosta, Aguiar-Curry, Travis Allen, Arambula, Baker, Berman, Bigelow, Bloom, Bonta, Brough, Burke, Caballero, Calderon, Carrillo, Cervantes, Chau, Chávez, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Dahle, Daly, Eggman, Flora, Fong, Frazier, Friedman, Gallagher, Gipson, Gloria, Gonzalez Fletcher, Gray, Grayson, Harper, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Quirk-Silva, Reyes, Rodriguez, Rubio, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Voepel, Waldron, Weber, Wood, Rendon
NO VOTE RECORDED: Cristina Garcia, Eduardo Garcia, Quirk
Prepared by: Stephanie Jordan / PUB. S. /
6/15/18 10:32:03
**** END ****
SENATE COMMITTEE ON PUBLIC SAFETY
Senator Nancy Skinner, Chair
2017 - 2018 Regular
Bill No: AB 2589 Hearing Date: June 12, 2018
Author: | Bigelow | ||
Version: | April 10, 2018 | ||
Urgency: | No | Fiscal: | No |
Consultant: | SJ | ||
Subject: Controlled Substances: Human Chorionic Gonadotropin
HISTORY
Source: California Veterinary Medical Association
Prior Legislation: None
Support: Unknown
Opposition: None known
Assembly Floor Vote: 75 - 0
PURPOSE
This purpose of this bill is to exempt human chorionic gonadotropin (hCG) from the regulations associated with Schedule III controlled substances when possessed by, sold to, purchased by, transferred to, or administered by a licensed veterinarian, or a licensed veterinarian’s designated agent, exclusively for veterinary use.
Existing law classifies controlled substances in five schedules according to their danger and potential for abuse. Schedule I controlled substances have the greatest restrictions and penalties, including prohibiting the prescribing of a Schedule I controlled substance. (Health & Saf. Code, §§ 11054-11058.)
Existing law classifies hCG as a Schedule III controlled substance. (Health & Saf. Code, § 11056, subd. (f)(32).)
Existing law makes the possession of a Schedule III controlled substance a misdemeanor, unless upon the prescription physician, dentist, podiatrist, or veterinarian, licensed to practice in this state, and punishable by imprisonment in a county jail for a period of not more than one year, except that such person may instead be punished pursuant to Penal Code section 1170 (h) if that person has one or more prior convictions for specified offenses. (Health & Saf. Code § 11377, subd. (a).)
This bill exempts hCG from the regulations associated with Schedule III controlled substances when possessed by, sold to, purchased by, transferred to, or administered by a licensed veterinarian, or a licensed veterinarian’s designated agent, exclusively for veterinary use.
COMMENTS
- Need for This Bill
According to the author:
California is one of five states that still broadly classifies hCG as a scheduled product for all uses. More than 45 states across the U.S. have either not scheduled hCG or have created an exemption for the use of hCG in cattle or other non-human species. The most recent states to align with federal law and enact this policy include: Nevada, North Carolina, West Virginia, Colorado and Idaho. See attached language from the states that recently passed similar legislation.
Health and Safety Code Section 11056 (f) (32) establishes California’s list of Schedule III Controlled Substances. Currently, this statute provides a general classification for human Chorionic Gonadotropin (hCG), placing it among anabolic steroids and without differentiating its use between animals and humans. However, hCG is not an anabolic steroid nor is it classified at the federal level as a controlled substance by the Drug Enforcement Agency.
Human Chorionic Gonadotropin (hCG) is a protein hormone that is used in cattle for treating ovarian cysts that cause perpetual estrus, or “heat.” This drug is administered as an injection into the muscle and is commonly used for livestock as an essential step for fertility treatment. It is also used to encourage spawning behavior in fish.
Unfortunately, California’s current Schedule III requirements of secure storage and recordkeeping for hCG place an unnecessary burden on veterinarians trying to care for large animal populations. This is a particular challenge for food animal veterinarians who treat cattle via large-scale mobile practices. This is especially problematic given the size of California’s dairy and cattle industry, respectively ranked numbers first and fourth in the country.
AB 2589 will exempt, for veterinary purposes only, the use of human Chorionic Gonadotropin (hCG) from the state’s storage and handling requirements imposed by the controlled substances list. This exemption will help California veterinarians treat animals more efficiently and effectively if it is expressly stored, sold, purchased, transferred, or administered for veterinary purposes. Under this measure, hCG would still remain a prescription product for veterinary use. The bill also clearly maintains hCG as a controlled substance for human use.
- Controlled Substance Schedules
Through the Controlled Substances Act of 1970, the federal government regulates the manufacture, distribution and dispensing of controlled substances. The Act groups drugs into five schedules with decreasing potential for physical or psychological harm, based on three considerations: (a) their potential for abuse; (b) their accepted medical use; and, (c) their accepted safety under medical supervision. Federal law includes relatively detailed explanations of the factors and standards for placement of drugs in the various schedules. California law does not explain how the schedules are organized.
- Schedule I controlled substances, such as heroin, ecstasy, and LSD, have a high potential for abuse and no generally accepted medical use.
- Schedule II controlled substances have a currently accepted medical use in treatment, or a currently accepted medical use with severe restrictions, and have a high potential for abuse and psychological or physical dependence. Schedule II drugs can be narcotics or non-narcotic. Examples of Schedule II controlled substances include morphine, methadone, Ritalin, Demerol, Dilaudid, Percocet, Percodan, and Oxycontin.
- Schedule III and IV controlled substances have a currently accepted medical use in treatment, less potential for abuse but are known to be mixed in specific ways to achieve a narcotic-like effect. Examples include drugs include Vicodin, Xanax, Ambien and other anti-anxiety drugs.
- Schedule V controlled substances have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics.
- Scheduling of Controlled Substances
California classifies controlled substances in five schedules according to their danger and potential for abuse. Schedule I controlled substances have the greatest restrictions and penalties, including prohibiting the prescribing of a Schedule I controlled substance. California does not have formal controlled substance classification procedure. Instead, California relies on the federal controlled substance schedule to determine the appropriateness of scheduling a particular substance.
21 United States Codes Section 811 gives the United States Attorney General the authority to add a controlled substance to the schedule or transfer a controlled substance between the schedules according to specific criteria. Before initiating proceedings to control a drug or other substance, remove a drug or other substance from the schedules, and after gathering the necessary data, the Attorney General requests from the Secretary of Health and Human Services a scientific and medical evaluation, and his or her recommendations, as to whether such drug or other substance should be so controlled or removed. The recommendations are required to include a recommendation with respect to the appropriate schedule. If the Attorney General determines if these facts and all other relevant data constitute substantial evidence of potential for abuse such as to warrant control or removal, he or she shall initiate proceedings for control or removal as the case may be.
The Attorney General is required to consider the following with respect to each drug or substance proposed to be controlled or removed from the schedules:
- Its actual or relative potential for abuse;
- Scientific evidence of its pharmacological effect, if known;
- The state of current scientific knowledge regarding the drug or other substance;
- Its history and current pattern of abuse;
- The scope, duration, and significance of abuse;
- What, if any, risk there is to the public health;
- Its psychic or physiological dependence liability; and,
- Whether the substance is an immediate precursor of a substance already controlled under this subchapter.
-- END --
Date of Hearing:
Chief Counsel: Gregory Pagan
ASSEMBLY COMMITTEE ON PUBLIC SAFETY
Reginald Byron Jones-Sawyer, Sr., Chair
ABPCA Bill Id:AB 2589
Author:(Bigelow) – As Amended Ver:April 10, 2018
SUMMARY:
Exempts human chorionic gonadotropin (hCG) from the regulations associated with Schedule III controlled substances when purchased by, transferred to, or administered by a licensed veterinarian, or licensed veterinarian's agent, exclusively for veterinary use.
EXISTING LAW:
- Classifies controlled substances in five schedules according to their danger and potential for abuse. Schedule I controlled substances have the greatest restrictions and penalties, including prohibiting the prescribing of a Schedule I controlled substance. (Health & Saf. Code, §§ 11054 to 11058.)
- Classifies hCG as a Schedule III controlled substance. (Health & Saf. Code, § 11056, subd. (f)(32).)
- Makes the possession of a Schedule III controlled substance a misdemeanor punishable by imprisonment in a county for a period of not more than one year, unless upon the prescription physician, dentist, podiatrist, or veterinarian, licensed to practice in this state. (Health & Saf. Code § 11377, subd. (a).)
FISCAL EFFECT:
Unknown
COMMENTS:
- Author's Statement: According to the author, "AB 2589 will help California veterinarians treat animals more efficiently and effectively by exempting hCG from the Controlled Substances Act if it is expressly stored, sold, purchased, transferred, or administered for veterinary purposes. Under this measure, hCG would still remain a prescription product for veterinary use. The bill also clearly maintains hCG as a controlled substance for human use."
- Federal Controlled Substance Schedules: Although there is no similar list of statutory criteria in California, this state generally follows federal classification procedure, as specified:
- Schedule I:
- The drug or other substance has a high potential for abuse.
- The drug or other substance has no currently accepted medical use in treatment in the United States.
- There is a lack of accepted safety for use of the drug or other substance under medical supervision.
- The drug or other substance has a high potential for abuse.
- Schedule II:
- The drug or other substance has a high potential for abuse.
- The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions.
- Abuse of the drug or other substances may lead to severe psychological or physical dependence.
- The drug or other substance has a high potential for abuse.
- Schedule III:
- The drug or other substance has a potential for abuse less than the drugs or other substances in Schedules I and II.
- The drug or other substance has a currently accepted medical use in treatment in the United States.
- Abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence.
- The drug or other substance has a potential for abuse less than the drugs or other substances in Schedules I and II.
- Schedule IV:
- The drug or other substance has a low potential for abuse relative to the drugs or other substances in Schedule III.
- The drug or other substance has a currently accepted medical use in treatment in the United States.
- Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in Schedule III.
- The drug or other substance has a low potential for abuse relative to the drugs or other substances in Schedule III.
- Schedule V:
- The drug or other substance has a low potential for abuse relative to the drugs or other substances in Schedule IV.
- The drug or other substance has a currently accepted medical use in treatment in the United States.
- Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in Schedule IV.
- The drug or other substance has a low potential for abuse relative to the drugs or other substances in Schedule IV.
- Schedule I:
- Scheduling of Controlled Substances: California classifies controlled substances in five schedules according to their danger and potential for abuse. Schedule I controlled substances have the greatest restrictions and penalties, including prohibiting the prescribing of a Schedule I controlled substance. California does not have formal controlled substance classification procedure. Instead, California relies on the federal controlled substance schedule to determine the appropriateness of scheduling a particular substance.
21 United States Codes Section 811 gives the United States Attorney General the authority to add a controlled substance to the schedule or transfer a controlled substance between the schedules according to specific criteria. Before initiating proceedings to control a drug or other substance, remove a drug or other substance from the schedules, and after gathering the necessary data, the Attorney General requests from the Secretary of Health and Human Services a scientific and medical evaluation, and his or her recommendations, as to whether such drug or other substance should be so controlled or removed. The recommendations are required to include a recommendation with respect to the appropriate schedule. If the Attorney General determines if these facts and all other relevant data constitute substantial evidence of potential for abuse such as to warrant control or removal, he or she shall initiate proceedings for control or removal as the case may be.
The Attorney General is required to consider the following with respect to each drug or substance proposed to be controlled or removed from the schedules:
- Its actual or relative potential for abuse;
- Scientific evidence of its pharmacological effect, if known;
- The state of current scientific knowledge regarding the drug or other substance;
- Its history and current pattern of abuse;
- The scope, duration, and significance of abuse;
- What, if any, risk there is to the public health;
- Its psychic or physiological dependence liability; and,
- Whether the substance is an immediate precursor of a substance already controlled under this subchapter.
- Its actual or relative potential for abuse;
REGISTERED SUPPORT / OPPOSITION:
Support
California Veterinary Medical Association
Opposition
None
Analysis Prepared by:
Gregory Pagan / PUB. S. / (916) 319-3744
Bill Author
Bill Co-Author(s):